Trending NewsTrending NewsNASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $11.86 -0.18 (-1.50%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$11.86 0.00 (0.00%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Stoke Therapeutics Stock (NASDAQ:STOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Stoke Therapeutics alerts:Sign Up Key Stats Today's Range$11.76▼$12.0350-Day Range$8.66▼$12.0452-Week Range$5.35▼$16.15Volume545,119 shsAverage Volume675,368 shsMarket Capitalization$647.52 millionP/E Ratio15.01Dividend YieldN/APrice Target$24.75Consensus RatingBuy Company Overview Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Read More Stoke Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreSTOK MarketRank™: Stoke Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 184th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Stoke Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is 15.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.34% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 4.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.59 Percentage of Shares Shorted23.34% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 4.79%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.04 News SentimentStoke Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows12 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,354.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Stoke Therapeutics is held by insiders.Read more about Stoke Therapeutics' insider trading history. Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Stock News HeadlinesGrit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winterJuly 13 at 6:47 AM | msn.comFive of the best beer gardens around Stoke-on-Trent to enjoy in the sunJuly 13 at 6:47 AM | msn.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 13 at 2:00 AM | Timothy Sykes (Ad)Man City prospect told to gain notoriety at Stoke CityJuly 13 at 6:47 AM | msn.comLille rival Aston Villa in race for Stoke’s Sol SidibéJuly 10 at 10:48 AM | sports.yahoo.comAston Villa want Stoke City midfielder Sol SidibeJuly 10 at 10:48 AM | sports.yahoo.comCouncil still against Stoke-on-Trent 'merger' as devolution decision gets nearerJuly 10 at 10:48 AM | msn.comStoke City close in on fourth summer signingJuly 10 at 10:48 AM | msn.comSee More Headlines STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $11.03 at the beginning of 2025. Since then, STOK stock has increased by 7.5% and is now trading at $11.86. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings results on Monday, March, 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The firm earned $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a net margin of 26.33% and a trailing twelve-month return on equity of 19.08%. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Top institutional investors of Stoke Therapeutics include Assenagon Asset Management S.A. (0.99%). Insiders that own company stock include Skorpios Trust, Edward M Md Kaye, Jonathan Allan, Barry Ticho and Stephen J Tulipano. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings3/24/2025Today7/13/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STOK CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Stoke Therapeutics$24.75 High Price Target$35.00 Low Price Target$18.00 Potential Upside/Downside+108.7%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.79 Trailing P/E Ratio15.01 Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.98 million Net Margins26.33% Pretax Margin27.00% Return on Equity19.08% Return on Assets15.72% Debt Debt-to-Equity RatioN/A Current Ratio8.41 Quick Ratio8.41 Sales & Book Value Annual Sales$190.91 million Price / Sales3.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book2.75Miscellaneous Outstanding Shares54,597,000Free Float49,410,000Market Cap$647.52 million OptionableOptionable Beta1.14 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:STOK) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.